Conference Coverage
Trending on the Eye Care Network
Latest News
Jul 25, 2026 | News
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
Functional OCT takes retinal imaging where structure alone cannot go
Jul 25, 2026
FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD
Jul 24, 2026
Q&A: How an AI platform cut screen failures and saved 4,000 hours in a retina practice
Jul 24, 2026
Danon disease: when the retina reveals a life-threatening cardiac disorder
Jul 23, 2026
Advertisement
Shorts
0:50
How newer IOLs are broadening premium lens candidacy
a day ago
0:24
Where does the field stand on functional outcomes in geographic atrophy?
4 days ago
0:21
How do baseline vision-loss predictors from the ARCHER study change GA patient counseling?
5 days ago
0:55
How the ENCELTO implant works, explained by Dr. Wykoff
5 days ago
0:41
AXPAXLI's real-world potential to reduce wet AMD treatment gaps
6 days ago
0:24
AI's future role in retina care recordkeeping, imaging, and research
6 days ago
1:16
Why every eye doctor should check dry eye first
6 days ago
0:21
Which baseline characteristics predict vision loss in geographic atrophy?
6 days ago
0:38
Treatment durability and Medicare status both drive retinal outcomes
7 days ago
1:00
AXPAXLI shows superiority in SOL-1 wet AMD trial
7 days ago
Digital Edition
Modern Retina
How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.
Ophthalmology Times
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Modern Retina
SOL-1 results show intravitreal axitinib hydrogel delivered superior vision
maintenance and anatomic outcomes through 52 weeks.
Ophthalmology Times Europe
Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges and multidisciplinary management of immune checkpoint inhibitor–associated uveitis
Ophthalmology Times Europe
AI models predicting retinal function from OCT could transform geographic atrophy assessment in clinical care and trials
Ophthalmology Times Europe
Utilize oral agents, diet and glucose monitoring systems when
acting to preserve vision
Ophthalmology Times Europe
Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure
Ophthalmology Times Europe
Examining the physiologic limits can help identify when its usage may be ineffective
Ophthalmology Times Europe
Understanding the different expectations between patients with these conditions is key to choosing the appropriate refractive surgery.
Ophthalmology Times
Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
Emerging dry eye therapies and co-managing MGD: Ping Moore, OD
Published: | Updated:
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with reassuring safety.
PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.
An ophthalmologist shares pearls for clinical practice.
Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, faster workflow.
David E. I. Pyott, CBE, MD(Hon), MBA, MA, discusses expanding subspecialty training and internationally recognized credentials in underserved regions.
Presenters highlight clinical insights and lessons from recent trial data and surgical experience
Creators on TikTok and YouTube share real LASIK journeys, bust myths, and help Gen Z and millennials explore modern vision correction options.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Building judgment and adaptability to navigate AI, gene therapy, and constant change.
Advertisement
A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.
Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.
Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.
The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.
Rising star in Ophthalmology, Nicholas Riina, MS, focuses on artificial intelligence and uses robotics training to enhance glaucoma diagnosis.
Advertisement
Advertisement